CDK9 inhibitors: A promising new treatment for hematological malignancies

A new research perspective was published in Oncotarget’s Volume 14 on August 7, 2023, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.”

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the

October 27, 2024

Clinical trial of vaccine candidate to prevent Lassa fever begins enrollment

A National Institutes of Health (NIH)-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants at the University of Maryland

March 17, 2025

Senators Grill NIH Director Nominee on Drug Prices, Gender-Affirming Care

WASHINGTON — Members of the Senate Health, Education, Labor and Pensions Committee questioned Monica Bertagnolli, MD, President Biden’s nominee to lead the National Institutes of

October 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.